Elucidating the specific pharmacological mechanism of motion (MOA) of naturally occurring compounds is often tough. Although Tarselli et al. (60) produced the 1st de novo artificial pathway to conolidine and showcased this naturally developing compound effectively suppresses responses to equally chemically induced and inflammation-derived pain, the pharmacologic target responsible https://www.proleviate.com/post/conolidine-an-alternative-natural-pain-relief-to-replace-traditional-painkillers